Journal Mobile Options
Table of Contents
Vol. 128, No. 2, 2012
Issue release date: August 2012
Acta Haematol 2012;128:83–87

Complete Response of Myeloid Sarcoma with FIP1L1-PDGFRA-Associated Myeloproliferative Neoplasms to Imatinib Mesylate Monotherapy

Tang T.-C. · Chang H. · Chuang W.-Y.
aDivision of Hematology-Oncology, and bDepartment of Pathology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Myeloid sarcoma (MS) is a localized, extramedullary tumor of acute myeloid leukemia (AML) that typically presents either de novo or concomitantly with myeloproliferative neoplasms (MPN), AML and myelodysplastic syndrome. Patients who have MS must be treated with intensive chemotherapy, as are patients with AML, because MS usually progresses to a systemic manifestation and leads to dismal outcomes. FIP1L1-PDGFRA-associated MPN, a subtype of myeloid and lymphoid neoplasm, is characterized by eosinophilia and abnormalities in the PDGFRA, PDGFRB or FGFR1 gene. Fusion of the FIP1L1 and PDGFRA genes activates the tyrosine kinase. As a result, imatinib mesylate (IM) is widely used for the treatment of this disorder. The coexistence of FIP1L1-PDGFRA-associated MPN and MS is extremely rare. Patients with this condition fail to achieve durable remission and long-term survival without a combination of intensive chemotherapy and IM. Here, we report a case of MS and FIP1L1-PDGFRA-associated MPN that was successfully treated with IM monotherapy.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, Piccaluga PP, Agostinelli C, Asioli S, Novero D, Bisceglia M, Ponzoni M, Gentile A, Rinaldi P, Franco V, Vincelli D, Pileri A Jr, Gasbarra R, Falini B, Zinzani PL, Baccarani M: Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 2007;21:340–350.
  2. Paydas S, Zorludemir S, Ergin M: Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma 2006;47:2527–2541.
  3. Yamauchi K, Yasuda M: Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer 2002;94:1739–1746.
  4. Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14–22.
  5. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201–1214.
  6. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P: Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia 2004;18:734–742.
  7. Cozzi P, Nosari A, Cantoni S, Ribera S, Pungolino E, Lizzadro G, Oreste P, Asnaghi D, Morra E: Traumatic left shoulder fracture masking aggressive granuloblastic sarcoma in a cml patient. Haematologica 2004;89:EIM15.
  8. Kuan JW, Pathmanathan R, Chang KM, Tan SM: Aleukemic bcr-abl positive granulocytic sarcoma. Leuk Res 2009;33:1574–1577.
  9. Bakst RL, Tallman MS, Douer D, Yahalom J: How I treat extramedullary acute myeloid leukemia. Blood 2011;118:3785–3793.
  10. Avni B, Rund D, Levin M, Grisariu S, Ben-Yehuda D, Bar-Cohen S, Paltiel O: Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma. Hematol Oncol 2012;30:34–40.

    External Resources

  11. Breccia M, Mandelli F, Petti MC, D’Andrea M, Pescarmona E, Pileri SA, Carmosino I, Russo E, De Fabritiis P, Alimena G: Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res 2004;28:1165–1169.

    External Resources

  12. Cho SF, Liu YC, Tsai HJ, Lin SF: Myeloid sarcoma mimicking nasopharyngeal carcinoma. J Clin Oncol 2011;29:e706–708.

    External Resources

  13. Chevallier P, Labopin M, Cornelissen J, Socie G, Rocha V, Mohty M: Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the acute leukemia working party of the European group for blood and marrow transplantation. Haematologica 2011;96:1391–1394.

    External Resources

  14. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Muller MC, Beneke H, Muller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Muller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Dohner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A: Recurrent finding of the FIP1L1-PDFGRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007;21:1183–1188.
  15. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J: Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alphapositive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005;19:286–287.
  16. Sekkach Y, Mekouar F, Jira M, Elqatni M, Elomri N, Fatihi J, Badaoui M, Hammi S, Smaali J, El Khattabi A, Amezyane T, Abouzahir A, Ghafir D: Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy (in French). Ann Pharm Fr 2011;69:277–281.
  17. Awano N, Ryu T, Yoshimura N, Takazoe M, Kitamura S, Tanaka M: Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia. Intern Med 2011;50:1741–1745.

    External Resources

  18. Helbig G, Hus M, Halasz M, Dudzinski M, Wieclawek A, Stachowicz M, Soja A, Kyrcz-Krzemien S: Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. Med Oncol 2012;29:1073–1076.
  19. Chan SW, Datta NN, Thomas TM, Chan KW: Intracranial chloroma in hypereosinophilic myelofibrosis. Surg Neurol 2003;59:55–57.

    External Resources

  20. Lynott A, Ravandi-Kashani F, Giles FJ: Malignancy: case report: hypereosinophilia progressing to granulocytic sarcoma and acute myelocytic leukemia with trisomy 8: a case report and review of the literature. Hematology 2000;4:487–493.
  21. Fujii N, Ikeda K, Takahashi N, Kojima K, Kobayashi Y, Ashiba A, Takenaka K, Fukuda S, Shinagawa K, Ishimaru F, Niiya K, Miura I, Tanimoto M, Harada M: Multilineage involvement in hypereosinophilic syndrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8. Br J Haematol 2002;119:716–719.

    External Resources

  22. Vedy D, Muehlematter D, Rausch T, Stalder M, Jotterand M, Spertini O: Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib. J Clin Oncol 2010;28:e33–e35.

    External Resources

  23. Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A, Calbecka M, Seferynska I, Razny M, Rodzaj M, Zuk E, Kyrcz-Krzemien S: Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. Cancer Chemother Pharmacol 2011;67:967–969.

    External Resources

  24. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D: Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007;109:4635–4640.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50